findmyKOL

Robert Foronjy, MD

Basic profile

State University of New York

ORCIDNPI
RegionBrooklyn, NY · NortheastSpecialtyPulmonary DiseaseFocusRespiratory
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2022Online presenceNot yet checkedPayments2021 onwardNIH funding2010–2025

Robert Foronjy is a Respiratory physician affiliated with State University of New York. OpenAlex indexes 156 publications with 3,711 citations (h-index 36).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
156publications

Distinct works indexed by OpenAlex, matched via ORCID.

3,711citations

Total citations across indexed works.

36h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
18companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 2010–2025

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

450 Clarkson Ave
Pulmonary And Critical Care Division
Brooklyn, NY 112032012

Telephone

718-270-1770

Registry record last updated 26 May 2015.

View the NPPES registry record

Industry payments

18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    85.6%
    Corticosteroid34.1%
    Trelegy Ellipta57%Breo Ellipta13%Budesonide-Formoterol Fumarate9%Fluticasone Propionate8%Breztri Aerosphere5%Symbicort3%Arnuity Ellipta2%Budesonide2%
    Part D<11 patients
    beta2-Adrenergic Agonist32.4%
    Albuterol Sulfate Hfa95%Ventolin Hfa5%
    Part D<11 patients

    + 3 more classes in this area

  • Metabolism & gastrointestinal

    7.3%
    Corticosteroid7.3%
    Prednisone100%
    Part D56 patients
  • Anti-infectives

    4.3%
    Tetracycline-class Drug3.6%
    Doxycycline Monohydrate100%
    Part D33 patients
    Short-acting sulfonamides0.7%
    Sulfamethoxazole-Trimethoprim100%
    Part D<11 patients
Where care is delivered (Part B)64.8% facility · 35.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 20102025 per NIH RePORTER. The latest:

6 more award records behind the reveal.Reveal →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”